Tarsus Pharmaceuticals, Inc. GAAP EPS of -$14.40 misses by $10.38, revenue of $194.5M beats by $3.72M
Open the sourceReported by Seeking Alpha, seekingalpha.com, 3 November 2026
45Impact 45 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at seekingalpha.com.
Named in this story
Tarsus Pharmaceuticals, Inc.